## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON Form 4 August 15, 201	I PHARMACEU	TICALS	INC							
FORM									OMB A	PROVAL
-	UNITED S	TATES S		ITIES AN hington, 1			NGE (	COMMISSION	OMB Number:	3235-0287
Check this I if no longer subject to Section 16. Form 4 or Form 5 obligations may continu <i>See</i> Instruct 1(b).	Filed purse ue. Section 17(a)	uant to Se ) of the Pi	ection 16 ublic Uti	<b>SECURI</b> (a) of the	TIES Securiti ing Com	ies Ez ipany	chang Act o	<b>NERSHIP OF</b> ge Act of 1934, f 1935 or Sectio 40	Expires: Estimated a burden hou response	•
(Print or Type Res	sponses)									
1. Name and Add GOLDSTEIN	dress of Reporting Po JOSEPH L	:   	Symbol REGENI	Name and ' ERON ACEUTI			g	5. Relationship of Issuer (Cheo X Director	ck all applicable	
(Last) 777 OLD SAV ROAD	(First) (Mi W MILL RIVER	(	3. Date of Earliest Transaction (Month/Day/Year) 08/14/2013					Officer (give below)	er (specify	
TARRYTOW	idment, Dat h/Day/Year)	e Original			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State) (Z	Zip)	Table	I - Non-De	rivative S	Securi	ties A c	quired, Disposed o	f or Beneficial	ly Owned
Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D.	ied Date, if	3. Transactio Code (Instr. 8) Code V	4. Securi	ties l (A) o l of (D	or 9) 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-
Common Stock	08/14/2013			С	5,000	А	\$ 0 (1)	5,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price Deriva Securit (Instr.
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Class A Stock	\$ 0 <u>(1)</u>	08/14/2013		С	5,000	(2)	(2)	Common Stock	5,000	\$ (

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
		Director	10% Owner	Officer	Other		
GOLDSTEIN JOSEPH L 777 OLD SAW MILL RIVEI TARRYTOWN, NY 10591	R ROAD	Х					
Signatures							
/s/**Joseph L. Goldstein	08/14/201	3					
**Signature of Reporting	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder.
- (2) These shares of Class A Stock are presently convertible and such conversion feature does not expire.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Person